Chugai opens a new U.S. R&D shop; UCB gets EU nod for epilepsy drug;

@FierceBiotech: TEDMED 2015: A brief history of CRISPR and what's next. Article | Follow @FierceBiotech

@JohnCFierce: To me, the FDA review of drisa reads like a letter to DMD parents. You don't want this drug. Please don't be angry.  | Follow @JohnCFierce

@DamianFierce: "Did you name me after the mayor of New York, dad?" "Yes, Kristaps, but he was just a basketball player then." | Follow @DamianFierce

> Japanese drugmaker Chugai Pharma opened a new U.S. hub in Berkeley Heights, NJ, an outpost focused on early-stage and translational research. More

> European regulators recommended approval of UCB's brivaracetam, a treatment for epilepsy the company plans to market as Briviact. Story

> Italian biotech Newron Pharmaceuticals raised $5.4 million in a private placement. Item

> Aptose Biosciences ($APTO) suspended dosing of the cancer drug APTO-253 in a Phase Ib trial over patient safety concerns, and the FDA has placed a clinical hold on the program. News

Medical Device News

@FierceMedDev: The top women in medical devices 2015. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: St. Jude earns FDA approval for recharge-free spinal cord stimulation system. Article | Follow @VarunSaxena2

@EmilyWFierce: Dx Digest: Invitae builds out cancer and epilepsy testing menus; Illumina gets in on autism research. More | Follow @EmilyWFierce

> Bard to buy Liberator for $181M to improve access to home care market. Article

> Cancer diagnostics company closes up shop after 6-year FTC investigation. More

> Philips launches smartphone plug-in ultrasound handheld with app in U.S. Story

Pharma News

@FiercePharma: Price controls loom for generic drugs in India next year. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Baxalta Singapore plant gets FDA OK to produce Advate. Report | Follow @EricPFierce

> Horizon drops hostile takeover attack on Depomed after legal ruling. Report

> Merck KGaA rolls out big plans for expansion in Africa. Story

> Dr. Reddy's strikes back at AstraZeneca in purple pill courtroom battle. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.